论文部分内容阅读
目的:探讨依达拉奉联合低分子肝素钙治疗脑血栓的疗效。方法:将50例脑血栓患者随机分为治疗组与对照组各25例,治疗组给予依达拉奉联合低分子肝素钙治疗,对照组仅给予肠溶阿司匹林治疗,比较2组患者的临床疗效。结果:治疗组和对照组的总有效率分别为96%、72%,治疗组显著优于对照组,2组比较,差异具有统计学意义(P<0.05)。结论:依达拉奉联合低分子肝素钙治疗脑血栓具有明确的疗效和很好的安全性,有利于患者早日康复,不良反应小,值得临床推广应用。
Objective: To investigate the therapeutic effect of edaravone combined with low molecular weight heparin on cerebral thrombosis. Methods: Fifty patients with cerebral thrombosis were randomly divided into treatment group and control group, with 25 cases in each group. The treatment group was treated with edaravone and low molecular weight heparin calcium, the control group was given aspirin alone. The clinical efficacy was compared between the two groups . Results: The total effective rate of the treatment group and the control group was 96% and 72%, respectively. The treatment group was significantly better than the control group. The difference was statistically significant (P <0.05). Conclusion: Edaravone combined with low-molecular-weight heparin in the treatment of cerebral thrombosis has definite curative effect and good safety, which is good for the patients to recover as soon as possible with less adverse reactions and is worthy of clinical application.